Drug and asset intelligence for Vardenafil Hydrochloride with 1 indexed intelligence signal across regulatory, clinical, competitive, and market developments.

Signals: 1
Catalysts: 0
Stage: Development stage unavailable

Sponsor company

Teva →

Recent signals(1)

RegulatoryAugust 15, 2026

Teva Pharmaceuticals receives AP status for Vardenafil Hydrochloride ANDA091347

Teva Pharmaceuticals has received Abbreviated Approval (AP) status for its ANDA091347 application for Vardenafil Hydrochloride, a treatment for erectile dysfunction.

Upcoming milestones

No catalysts indexed for this entity yet.

Related catalysts

No catalysts indexed for this entity yet.

Indications

No related entities indexed yet.

Therapeutic areas

Erectile Dysfunction →

Urology →

Newsletter

Get signals before the market moves

Concise strategic intelligence on regulatory, clinical, competitive, and market developments — free to subscribe.

No paywall. No spam. Unsubscribe anytime.